Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356460 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
A Phase 1 study of Melanoma and Carcinoma, Renal Cell, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 6
- Study locations
NCT00356460 is a Phase 1 study of Melanoma and Carcinoma, Renal Cell that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 29 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00356460, a Phase 1 study of Melanoma and Carcinoma, Renal Cell, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma.
Conditions Studied
Interventions
- BIOLOGICAL GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Study Locations (6)
Massachusetts
- Dana Farber/Harvard Cancer Center, Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Cambridge
Maryland
- National Cancer Institute (NCI) - Bethesda
New Jersey
- Cancer Institute of New Jersey - New Brunswick
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356460
The ClinicalTrials.gov registry entry for NCT00356460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody is the first listed.
NCT00356460 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00356460 about?
NCT00356460 is a clinical study titled "Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma". The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma.
What is the current status of trial NCT00356460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-09. Estimated completion is 2009-05.
What conditions does trial NCT00356460 study?
This clinical trial studies the following conditions: Melanoma, Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00356460?
The interventions under investigation include: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT00356460?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00356460 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.